JAML promotes CD8 and γδ T cell antitumor immunity and is a novel target for cancer immunotherapy

T cells are critical mediators of antitumor immunity and a major target for cancer immunotherapy. Antibody blockade of inhibitory receptors such as PD-1 can partially restore the activity of tumor-infiltrating lymphocytes (TILs). However, the activation signals required to promote TIL responses are...

Descripción completa

Detalles Bibliográficos
Autores principales: McGraw, Joseph M., Thelen, Flavian, Hampton, Eric N., Bruno, Nelson E., Young, Travis S., Havran, Wendy L., Witherden, Deborah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404475/
https://www.ncbi.nlm.nih.gov/pubmed/34427588
http://dx.doi.org/10.1084/jem.20202644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404475/
https://www.ncbi.nlm.nih.gov/pubmed/34427588
http://dx.doi.org/10.1084/jem.20202644

Ejemplares similares